Biophytis S.A.
Clinical-stage biotech developing therapeutics for age-related degenerative diseases.
ALBPS | PA
Overview
Corporate Details
- ISIN(s):
- FR0012816825 (+4 more)
- LEI:
- 9695008GIE061NBGU106
- Country:
- France
- Address:
- 14 AVENUE DE L'OPERA, 75001 PARIS
- Website:
- https://www.biophytis.com/en/
Description
Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2017-06-16 18:00 |
Résultats de l’Assemblée Générale Mixte du 16 juin 2017 Nomination de Jean M. F…
|
French | 724.6 KB | ||
| 2017-06-16 18:00 |
Results of the General Shareholders’ Meeting held on June 16, 2017 Appointment …
|
English | 713.7 KB | ||
| 2017-06-15 17:59 |
BIOPHYTIS sélectionne SGS Life Science Services pour conduire MACA-PK, étude cl…
|
French | 771.0 KB | ||
| 2017-06-15 17:59 |
BIOPHYTIS selects SGS Life Science Services to conduct MACA-PK, clinical study …
|
English | 774.4 KB | ||
| 2017-05-16 08:00 |
Biophytis annonce l’émission d’une tranche d’ORNANEBSA d’un montant de 3,0 M€
|
French | 711.3 KB | ||
| 2017-05-16 08:00 |
Biophytis announces the issuance of a €3 million tranche of ORNANEBSA
|
English | 926.4 KB | ||
| 2017-05-11 07:59 |
Biophytis : First patient-in in the United States and opening of 2 clinical cen…
|
English | 828.4 KB | ||
| 2017-05-11 07:59 |
Biophytis : Recrutement du premier patient aux Etats-Unis de l’étude SARA-OBS d…
|
French | 848.3 KB | ||
| 2017-05-03 18:28 |
BIOPHYTIS confirms that Sarconeos modulates the Renin-Angiotensin System and ac…
|
English | 773.3 KB | ||
| 2017-05-03 18:28 |
BIOPHYTIS confirme que Sarconeos module le système Rénine-Angiotensine et agit …
|
French | 953.4 KB | ||
| 2017-04-04 07:31 |
Biophytis sécurise le financement de son étude clinique de phase 2b dans la sar…
|
French | 909.2 KB | ||
| 2017-04-04 07:31 |
Biophytis secures funding for phase 2B clinical trial in Sarcopenia, SARA-INT
|
English | 1007.8 KB | ||
| 2017-03-27 08:01 |
Biophytis ouvre les premiers centres cliniques en Europe ?et démarre le recrute…
|
French | 827.3 KB | ||
| 2017-03-27 08:01 |
Biophytis opens the first clinical centers in Europe and starts ?the recruitmen…
|
English | 825.9 KB | ||
| 2017-03-21 18:04 |
BIOPHYTIS : Quatre travaux scientifiques sélectionnés pour présentation à l’Int…
|
French | 788.8 KB |
Automate Your Workflow. Get a real-time feed of all Biophytis S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Biophytis S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Biophytis S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-11-22 | N/A | Other | Buy | 8,443,190 | 79,365.99 EUR |
| 2020-12-16 | N/A | Other | Sell | 500,000 | 499,000.00 EUR |
| 2020-12-16 | N/A | Other | Other | 313,417 | N/A |
| 2020-04-30 | N/A | Other | Other | 2,955,701 | 177,342.06 EUR |
Peer Companies
